Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Prif Awduron: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
Elsevier
2019
|
Crynodeb: |
---|